September 08, 2026

FDA approves serial liquid biopsy testing

In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.

MDSpire News

September 03, 2026

AI cuts lesion measurement time by 34%

Automated lesion measurements increased agreement on treatment response, although expert-generated proposals were accepted more often and required fewer adjustments.

MDSpire News

September 03, 2026

Google clinical leader on health care’s AI ‘epistemic shift’

“AI is in its infancy. It’s as bad as it will ever be right now, and the rate of change is remarkable.”

MDSpire News

September 03, 2026

AI poised to reshape care

“This is really a unique time in our careers to see such a large change in technology."

MDSpire News

September 01, 2026

What happens to clinical skills when AI does the routine work?

“The need to be extra vigilant when you're reviewing something versus doing it from scratch can be a real problem.”

MDSpire News

September 01, 2026

10 Growing US Metro Areas to Consider for Private Practice

These 10 metropolitan areas recorded population growth and had recently completed, ongoing, or announced health care infrastructure projects.

MDSpire News

September 01, 2026

FDA expands essential thrombocythemia care

Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.

MDSpire News

August 31, 2026

FDA approves hepcidin mimetic for PV

Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.

MDSpire News

August 28, 2026

Newborn variants may flag childhood cancer predisposition

Targeted sequencing identified cancer-risk variants in about 7% of pediatric patients who later developed early-onset solid or brain malignancies.

MDSpire News

August 28, 2026

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News